Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hansoh Pharmaceutical Group CoHNSPF 92 Cyclically Adjusted PS Ratio is 14.71 as of Jul. 20, 2026, which is 22% below its 10-year median of 18.80. GuruFocus rates HNSPF with a GF Score™ of 92/100 and a GF Value™ of $3.66 (Fairly Valued). Among 751 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks worse than 96.27% on this metric.
The historical rank and industry rank for Hansoh Pharmaceutical Group Co's Cyclically Adjusted PS Ratio or its related term are showing as below:
HNSPF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 15.33 Med: 18.8 Max: 22.99
Current: 17.04
During the past 10 years, Hansoh Pharmaceutical Group Co's highest Cyclically Adjusted PS Ratio was 22.99. The lowest was 15.33. And the median was 18.80.
HNSPF's Cyclically Adjusted PS Ratio is ranked worse than 96.27% of 751
companies
in the Drug Manufacturers industry
Industry Median: 2.01
vs HNSPF: 17.04
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Hansoh Pharmaceutical Group Co's adjusted revenue per share data of for the fiscal year that ended in Dec25 was $0.357. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.26 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Hansoh Pharmaceutical Group Co (OTCPK:HNSPF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Hansoh Pharmaceutical Group Co Cyclically Adjusted PS Ratio Related Terms
Hansoh Pharmaceutical Group Co Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co Cyclically Adjusted PS Ratio Chart
HNSPF vs ZTS, UTHR: Cyclically Adjusted PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's Cyclically Adjusted PS Ratio falls into.
Hansoh Pharmaceutical Group Co Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 14.71 mean?
Hansoh Pharmaceutical Group Co (HNSPF) has a Cyclically Adjusted PS Ratio of 14.71 as of Jul. 20, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hansoh Pharmaceutical Group Co and its competitors. This is 22% below median its historical median of 18.80. Over the past decade, Hansoh Pharmaceutical Group Co's Cyclically Adjusted PS Ratio has ranged from 15.33 to 22.99. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #723 out of 751 companies in the Drug Manufacturers industry, placing it in the top 96.3%.
Is Hansoh Pharmaceutical Group Co's Cyclically Adjusted PS Ratio too high?
Hansoh Pharmaceutical Group Co's current Cyclically Adjusted PS Ratio of 14.71 is 22% below median its 10-year median of 18.80. Over the past 10 years, this metric has ranged from a low of 15.33 to a high of 22.99. The Drug Manufacturers industry median Cyclically Adjusted PS Ratio is 2.01. Hansoh Pharmaceutical Group Co's value of 14.71 is 631.8% above this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #723 out of 751 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Cyclically Adjusted PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #723 out of 751 companies for Cyclically Adjusted PS Ratio. This places Hansoh Pharmaceutical Group Co in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.01. Hansoh Pharmaceutical Group Co's value of 14.71 is 631.8% above this benchmark. Historically, Hansoh Pharmaceutical Group Co's own Cyclically Adjusted PS Ratio has ranged from 15.33 to 22.99 over the past decade. While the company's 10-year median is 18.80 vs. the industry median of 2.01, Hansoh Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PS Ratio among Drug Manufacturers companies is 2.01, based on 751 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current Cyclically Adjusted PS Ratio of 14.71 is 631.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PS Ratio is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current Cyclically Adjusted PS Ratio is 14.71, which is 22% below median its own 10-year median of 18.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Fairly Valued. The stock's GF Value™ is $3.66, compared to a current price of $3.83 — trading 4.5% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 14.71, which is 22% below median its 10-year median of 18.80 and 631.8% above the Drug Manufacturers industry median of 2.01. Hansoh Pharmaceutical Group Co's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current Cyclically Adjusted PS Ratio is 14.71 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $3.83 is trading 4.5% above its estimated GF Value™ of $3.66.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for HNSPF:
Cyclically Adjusted PS Ratio: 14.71 (22% below median its 10-year median of 18.80)
GF Value™: $3.66 vs. price of $3.83 (4.5% above fair value)
Industry Position: 631.8% above the Drug Manufacturers median (#723 of 751)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Business Description
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
92GF Score
Get the complete analysis for HNSPF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
